Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;40(5):458-465.
doi: 10.1007/s11604-021-01231-4. Epub 2022 Jan 1.

Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy

Masanori Someya  1 , Yuki Fukushima  2 , Tomokazu Hasegawa  2 , Takaaki Tsuchiya  2 , Mio Kitagawa  2 , Toshio Gocho  2 , Shoh Mafune  2 , Yutaro Ikeuchi  2 , Yoh Kozuka  2 , Yoshihiko Hirohashi  3 , Toshihiko Torigoe  3 , Masahiro Iwasaki  4 , Motoki Matsuura  4 , Tsuyoshi Saito  4 , Koh-Ichi Sakata  2
Affiliations
Review

Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy

Masanori Someya et al. Jpn J Radiol. 2022 May.

Abstract

Human papillomavirus (HPV)-related cancer is one of the diseases entities for which the applications of radiotherapy have been increasing. Recently, the process of carcinogenesis from HPV infection and the mechanism of tumor immunity that develops during disease progression have been elucidated. In this review, we will describe the mechanism of tumor immunity and how chemoradiotherapy may overcome and improve the efficacy of tumor immunity. We will also discuss the usefulness of proteins involved with tumor immunity as a predictive marker of radiotherapy response, and present an overview of ongoing clinical trials of combinations of immune checkpoint inhibitors and radiotherapy to demonstrate the promising combination therapy that has been currently emerging.

Keywords: CD8; CD8 based subtyping; Cervical cancer; Forkhead box P3; Human leukocyte antigen class I; Programmed death ligand 1; Radiotherapy; Tumor immunity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CD8-positive T cell-based classification of the cancer microenvironment. (A) Inflamed type: defects in tumor recognition by T cells, (B) Excluded type: failure of T cell infiltration into the tumor, (C) Cold type: lack of antigen presentation of tumor cells
See this image and copyright information in PMC

References

    1. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014;26:13–21. doi: 10.1016/j.semcancer.2013.11.002. - DOI - PubMed
    1. Schellenbacher C, Roden RBS, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017;231:166–175. doi: 10.1016/j.virusres.2016.11.020. - DOI - PMC - PubMed
    1. Haedicke J, Iftner T. Human papillomaviruses and cancer. Radiother Oncol. 2013;108(3):397–402. doi: 10.1016/j.radonc.2013.06.004. - DOI - PubMed
    1. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–435. doi: 10.1002/path.4424. - DOI - PubMed
    1. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine. 2009;29(27 Suppl 1):A46–53. doi: 10.1016/j.vaccine.2008.10.085. - DOI - PubMed